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GNRH1 mutations in patients with idiopathic hypogonadotropic
hypogonadism
Abstract
Idiopathic hypogonadotropic hypogonadism (IHH) is a condition characterized by failure to undergo
puberty in the setting of low sex steroids and low gonadotropins. IHH is due to abnormal secretion or
action of the master reproductive hormone gonadotropin-releasing hormone (GnRH). Several genes
have been found to be mutated in patients with IHH, yet to date no mutations have been identified in the
most obvious candidate gene, GNRH1 itself, which encodes the preprohormone that is ultimately
processed to produce GnRH. We screened DNA from 310 patients with normosmic IHH (nIHH) and
192 healthy control subjects for sequence changes in GNRH1. In 1 patient with severe congenital nIHH
(with micropenis, bilateral cryptorchidism, and absent puberty), a homozygous frameshift mutation that
is predicted to disrupt the 3 C-terminal amino acids of the GnRH decapeptide and to produce a
premature stop codon was identified. Heterozygous variants not seen in controls were identified in 4
patients with nIHH: 1 nonsynonymous missense mutation in the eighth amino acid of the GnRH
decapeptide, 1 nonsense mutation that causes premature termination within the GnRH-associated
peptide (GAP), which lies C-terminal to the GnRH decapeptide within the GnRH precursor, and 2
sequence variants that cause nonsynonymous amino-acid substitutions in the signal peptide and in
GnRH-associated peptide. Our results establish mutations in GNRH1 as a genetic cause of nIHH.
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Idiopathic hypogonadotropic hypogonadism (IHH) is a condition char-
acterized by failure to undergo puberty in the setting of low sex
steroids and low gonadotropins. IHH is due to abnormal secretion or
action of the master reproductive hormone gonadotropin-releasing
hormone (GnRH). Several genes have been found to be mutated in
patients with IHH, yet to date no mutations have been identified in
the most obvious candidate gene, GNRH1 itself, which encodes the
preprohormone that is ultimately processed to produce GnRH. We
screened DNA from 310 patients with normosmic IHH (nIHH) and 192
healthy control subjects for sequence changes in GNRH1. In 1 patient
with severe congenital nIHH (with micropenis, bilateral cryptorchid-
ism, and absent puberty), a homozygous frameshift mutation that is
predicted to disrupt the 3 C-terminal amino acids of the GnRH
decapeptide and to produce a premature stop codon was identified.
Heterozygous variants not seen in controls were identified in 4
patients with nIHH: 1 nonsynonymous missense mutation in the
eighth amino acid of the GnRH decapeptide, 1 nonsense mutation
that causes premature termination within the GnRH-associated pep-
tide (GAP), which lies C-terminal to the GnRH decapeptide within the
GnRH precursor, and 2 sequence variants that cause nonsynonymous
amino-acid substitutions in the signal peptide and in GnRH-associated
peptide. Our results establish mutations in GNRH1 as a genetic cause
of nIHH.
GnRH  luteinizing hormone-releasing hormone  LHRH
Gonadotropin-releasing hormone (GnRH) is the master hor-mone of the reproductive endocrine system. The existence
of central hormones that regulate reproduction was postulated
a century ago (reviewed in ref. 1). In 1910, Crowe et al. (2)
demonstrated that disruption of the hypothalamic-pituitary con-
nection in dogs prevented the onset of puberty. Subsequent
studies led to the hypothesis that the pituitary is controlled by a
hypothalamic factor (3–6). It was not until 1971, however, that
the amino acid sequence of GnRH was determined after ex-
traction from the hypothalami of thousands of pigs and sheep by
the groups of Schally and Guillemin (7, 8).
The neurons that secrete GnRH arise in the olfactory placode
and migrate into the hypothalamus (reviewed in ref. 1). Once in
the hypothalamus, these GnRH neurons project axons to the
median eminence and synchronize their secretion of GnRH in a
pulsatile fashion. GnRH is then carried by the portal circulation
to the pituitary gland and stimulates the gonadotropes of the
anterior pituitary to secrete the gonadotropins follicle-
stimulating hormone (FSH) and luteinizing hormone (LH).
These gonadotropins then evoke steroidogenesis and gameto-
genesis from the gonads.
Complementing extensive physiologic studies of the central
role of GnRH in reproduction (reviewed in ref. 1), human
genetic studies have underscored the critical role of GnRH in
regulating reproduction (reviewed in refs. 9, 10). Idiopathic
hypogonadotropic hypogonadism (IHH) is characterized by the
absence of spontaneous pubertal development in the face of low
sex steroid and gonadotropin levels with otherwise normal
pituitary function. When associated with anosmia, this hypogo-
nadotropism is termed Kallmann syndrome (KS), whereas iso-
lated hypogonadotropic hypogonadism with a normal sense of
smell is termed normosmic IHH (nIHH). Studies of patients
with nIHH and KS have led to the identification of several genes
that regulate reproduction. Mutations in KAL1 (11, 12), FGFR1
(13), FGF8 (14), PROK2 (15), PROKR2 (15), and CHD7 (16) are
thought to disrupt the development and migration of GnRH
neurons, thereby resulting in KS and/or nIHH. Patients with
mutations in PCSK1, which encodes prohormone convertase 1/3,
exhibit hypogonadotropic hypogonadism because of abnormal
processing of the GnRH decapeptide from its prohormone
precursor (17). Mutations in GPR54 cause nIHH by interfering
with the normal secretion of GnRH (18, 19), and mutations in
GNRHR, which encodes the GnRH receptor, result in inability
to respond to GnRH (20). Mutations in the genes TAC3 and
TACR3, which encode neurokinin B and its receptor, respec-
tively, have recently been implicated in nIHH (21), although
their precise functions in reproduction remain unclear.
A glaring omission from the list of genes implicated in IHH is
GNRH1 itself, which encodes the preprohormone that is ulti-
mately processed to produce GnRH. Findings in the mouse
certainly suggest that human mutations in GNRH1 would cause
nIHH. The hpg mouse carries a deletion of Gnrh1 that arose
spontaneously and results in complete absence of GnRH syn-
thesis (22, 23). Male and female hpg mice are sexually infantile,
infertile, and exhibit low sex steroid and gonadotropin levels
(22). In one of the earliest demonstrations of successful gene
therapy, the reproductive deficits of hpg mice were rescued by a
Gnrh1 transgene (24). Aside from their reproductive pheno-
types, hpg mice appear grossly normal, although dental abnor-
malities have recently been reported (25). The clear association
of loss of Gnrh1 function in the mouse with hypogonadotropic
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hypogonadism makes the absence of human GNRH1 mutations
as a cause of nIHH all the more puzzling.
We herein report a homozygous mutation in a male patient
with severe congenital nIHH. This single base-pair deletion
produces a frameshift that is predicted to disrupt the GnRH
decapeptide. We also identified rare heterozygous GNRH1
sequence variants in 4 patients with nIHH.
Results
Patient Phenotypes. Patient 1. Patient 1 was evaluated at 8 years, 8
months, for cryptorchidism and microphallus. His parents had
normal pubertal timing, come from the same village in Armenia,
and deny consanguinity (Fig. 1A). The patient’s examination was
notable for height between the 10th and 25th percentiles, weight
between the 75th and 90th percentiles, nonpalpable testes,
microphallus (3 cm), and absence of midline or skeletal
defects. FSH and LH were both0.5 international units (IU)/L,
and anti-Mu¨llerian hormone was 99 pmol/L (reference range for
prepubertal boys, 100–300 pmol/L), indicating the presence of
testicular Sertoli cells. A human chorionic gonadotropin (hCG)
stimulation test at 9 years produced no change in serum testos-
terone (from 0.38 to 0.4 nmol/L). Ultrasound identified inguinal
testes with calculated volumes of 0.13 and 0.11 mL. Shortly
thereafter, he underwent bilateral orchiopexy. Intraoperative bi-
lateral testicular biopsies showed immature seminiferous tubules
with no lumen, gonocyte-like cells, immature Sertoli cells, and
interstitial fibrosis with spindle-shaped myofibroblasts (Fig. 1B).
At age 13 years, 6 months, a GnRH stimulation test was
performed because of lack of pubertal development. Baseline
FSH and LH were both0.5 IU/L and rose minimally to 1.3 and
0.8 IU/L, respectively. Formal smell testing with a set of odorants
revealed a normal sense of smell. He began treatment with
testosterone enanthate 100 mg every 4 weeks, which resulted in
linear growth and development of secondary sexual character-
istics. Currently, at age 15 years, 6 months, his height is 168 cm
(50th percentile), his weight is 81 kg, and he has developed facial
hair and Tanner V pubic hair.
Patient 2. Patient 2 presented at 19 years with absence of breast
development and was diagnosed with nIHH. She conceived 1
singleton and 1 twin pregnancy after gonadotropin treatment
GNRH1 G29GfsX12/G29GfsX12
Patient 1A
B
normosmic IHH
*
*
Fig. 1. Features of patient 1, who has a homozygous frameshift mutation in
GNRH1. (A) Pedigree. Arrow, proband. (B) Testicular biopsy of patient 1,
stained with hematoxylin and eosin. [Magnification: 1,000.] Arrows,
gonocyte-like cells; asterisks, interstitial cells.
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Fig. 2. Pedigrees of patients with nIHH found to have heterozygous sequence variants in GNRH1. Arrows, probands; , wild type.
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(Fig. 2). At age 42 years, she exhibited reversal of IHH, with
normal menstrual cycles after stopping hormonal therapy.
The patient’s eldest daughter presented at 14 years with
primary amenorrhea and Tanner III breast development,
whereas her younger twin daughters were started on estrogen
therapy at 13 years for absent puberty (Fig. 2). The diagnosis of
nIHH was confirmed in her daughters when they failed to
resume menses after discontinuation of hormonal therapy at age
18. Patient 2’s two paternal aunts also have nIHH, and her niece
has hypothalamic amenorrhea (Fig. 2).
Genetic analysis of this patient identified a heterozygous
mutation in FGFR1 (p.I239T) and a heterozygous variant in
PROKR2 (p.S202G) (Table 1 and Fig. 2). The patient’s twin
daughters and niece do not carry the PROKR2 variant, and one
of the patient’s daughters carries the FGFR1 mutation (Fig. 2).
Patient 3. Patient 3 was a product of a normal delivery at term
after a benign pregnancy. He had descended testes at birth, but
the left testis was retractile at 5 days. At 7 years, he underwent
left inguinal hernia repair and left orchiopexy. Acne developed
at age 11. He had a history of febrile seizures and received
phenobarbital prophylaxis until age 14. His father was reported
to be a ‘‘delayed bloomer’’ (Fig. 2).
The patient was evaluated at 17 years, 6 months, for absent
puberty. His physical examination was notable for a high-pitched
voice, mild acne on the chin, absence of facial hair, sparse
axillary hair, a few strands of pubic hair, microphallus (length 2.5
cm), right testicle with length of 2 cm and soft consistency, left
testicle with length of 1 cm, and intact olfaction as tested by serial
dilutions of pyridine solutions. Laboratory evaluation was no-
table for testosterone, 1.9 nmol/L; FSH, 2 IU/L; and LH, 4–6
IU/L. Karyotype was 46,XY. After an hCG stimulation test
(5,000 IU daily for 5 days), testosterone rose from 1.9 to 3.0
nmol/L. After a clomiphene stimulation test, FSH, LH, and
testosterone were essentially unchanged. Bone age was 15 years.
He was treated with escalating doses of intramuscular testoster-
one for 10 months and reported little response.
At age 22 years, 5 months, the patient underwent detailed
laboratory evaluation at Massachusetts General Hospital
(MGH). Aside from hypogonadotropic hypogonadism, he had
normal anterior pituitary function. Frequent sampling for 12 h
showed absence of LH pulses (Fig. S1A). A 7-day challenge with
pulsatile GnRH resulted in progressive increases in FSH and
LH, but his testosterone level remained low (Fig. S1B). A
computed tomography scan of the sella was normal. A right
testicular biopsy performed at age 22 years, 11 months, showed
small seminiferous tubules and complete absence of Leydig cells,
consistent with gonadotropin deficiency. Bone age was 17 years.
Subsequent treatment with pulsatile GnRH therapy for 1 year
resulted in normalization of serum testosterone levels, elevated
gonadotropin levels, and increase in testicular size to 5–6 mL
bilaterally.
Patient 4. Patient 4 was born to Chinese/Cambodian parents who
were first cousins (Fig. 2), and he had a small penis at birth. He
was evaluated at 16 years for absence of secondary sexual
characteristics. Treatment with escalating doses of intramuscular
testosterone enanthate induced development of secondary sex-
ual characteristics. At 26 years, testes were 3 mL bilaterally.
Smell testing with the University of Pennsylvania Smell Identi-
fication Test revealed a normal sense of smell. The patient also
has progressive visual loss that started at 9 years because of
retinitis pigmentosa.
Patient 5. Patient 5’s detailed medical and family history has been
reported in ref. 26. The patient and his nephew are hemizygous
for a frameshift mutation in NR0B1 (also called DAX1) (Table
1 and Fig. 2) and consequently have X-linked adrenal hypoplasia
congenita, with primary adrenal insufficiency and nIHH. The
patient’s mother, sister, and niece had delayed puberty and
are heterozygous for the NR0B1/DAX1 mutation (Fig. 2 and
Table 1).
Sequence Changes in GNRH1. GNRH1 consists of 3 coding exons
(Fig. 3), which encode a 92-aa preprohormone that is processed
to produce the GnRH decapeptide and the GnRH-associated
peptide (GAP) (1). DNA from 310 patients with nIHH and 192
control subjects underwent sequencing of theGNRH1 exons and
exon–intron boundaries.
A homozygous frameshift mutation ([c.87delA]  [c.87delA],
[p.G29GfsX12]  [p.G29GfsX12]) was identified in patient 1
(Table 1 and Fig. 3). This change lies in the codon encoding the
sixth amino acid of the GnRH decapeptide and is predicted to
alter all amino acids C-terminal to this residue, with premature
termination after 11 aa (Fig. 3).
Four heterozygous sequence variants not seen in control
subjects were found in nIHH patients (Table 1 and Fig. 3).
Patient 2 has a rare variant resulting in an amino-acid substitu-
tion in the eighth residue of the GnRH decapeptide ([c.91CT]
 [], [p.R31C]  []) (Table 1 and Fig. 3). The same
heterozygous change in GNRH1 was found in the patient’s twin
daughters and niece (Fig. 2). Patient 3 carries a heterozygous
rare variant ([c.217CT]  [], [p.R73X]  []) that causes
premature termination in the GAP region of the GnRH pre-
cursor (Table 1 and Fig. 3). This change was also found in his
sister (Fig. 2). Patient 4 is heterozygous for the variant
[c.172AT]  [], [p.T58S]  [], which causes an amino acid
substitution in a nonconserved residue in the GAP region.
Patient 5 carries a heterozygous rare variant ([c.52GA]  [],
[p.V18M]  []) that alters an amino acid in the signal peptide.
This amino acid change is not predicted to alter signal peptide
recognition or cleavage. The patient’s mother, sister, and niece
also carry this variant (Fig. 2).
SNP rs6185 was seen in 135 (22%) of the 620 patient alleles
and 133 (35%) of the 384 control alleles; the reported allele
frequency of this SNP is 18–30% in Caucasians and 52–61% in
Table 1. Phenotypes of nIHH probands with GNRH1 variants
Subject Sex Base pair change Amino acid change Ethnicity Inheritance Notable phenotypes
Other gene
variants
1 1898001 M c.87delA  c.87delA p.G29GfsX12  p.G29GfsX12 Caucasian Sporadic Bilateral cryptorchidism,
microphallus
None identified
2 79701 F c.91CT   p.R31C   Caucasian Familial Reversal at age 42 FGFR1, PROKR2
3 08901 M c.217CT   p.R73X   Caucasian Familial Right retractile testis,
microphallus
None identified
4 1820001 M c.172AT   p.T58S   Asian Sporadic Microphallus, retinitis
pigmentosa
None identified
5 12301 M c.52GA   p.V18M   Caucasian Familial Adrenal insufficiency NR0B1/DAX1
F, female; M, male.
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Asians.* One patient and one control subject were found to be
heterozygous for SNP rs6186, which has an allele frequency
of 1–4%.*
Discussion
We have identified a homozygous frameshift mutation in
GNRH1 in a patient with severe nIHH. This establishes GNRH1
as a cause of nIHH. We also identified rare heterozygous
sequence variants in GNRH1 in 4 nIHH patients of 310 patients
screened.
The frameshift mutation in patient 1 is unquestionably null
because the C terminus of GnRH is essential for its function
(reviewed in ref. 27). Patient 1’s severe phenotype is consistent
with complete loss of GnRH activity. His minimal rise in
gonadotropins after administration of exogenous GnRH indi-
cates lack of prior exposure to GnRH, and his history of
microphallus and cryptorchidism underscores the importance of
GnRH for penile growth and testicular descent during fetal
development (28).
GNRH1 expression in the placenta has been well described
(29), but patient 1’s gestation and delivery demonstrates that
zygotic GnRH is not strictly required for placental function.
Indeed, GNRH1 expression has been described in a number of
other tissues, including prostate, retina, and developing teeth
(25, 30, 31), but the fact that patient 1 exhibits no obvious
phenotypes aside from IHH argues against a critical function for
GNRH1 in these tissues. GnRH is also expressed in the testes
(32), and at face value patient 1’s subnormal response to hCG
stimulation might suggest a direct role for GnRH in the testes.
However, his Leydig cell dysfunction could be a result of his
cryptorchidism or his hypogonadotropism during development,
because patients with severe nIHH require months of gonado-
tropin or pulsatile GnRH therapy to achieve Leydig cell matu-
ration and normalization of serum testosterone (33). Thus, his
poor response to hCG does not necessarily indicate a direct
function of GnRH in the testes. To the contrary, his testicular
biopsy did not reveal any obvious abnormalities.
The R31C change in patient 2 alters the eighth amino acid of
the GnRH decapeptide. Substitutions of histidine, glutamine,
leucine, serine, tyrosine, or tryptophan at this position markedly
reduce the ability of GnRH to bind and activate mammalian
GnRH receptors (34, 35). Lu et al. (35) propose that the human
GnRH receptor has evolved to specifically recognize this argi-
nine residue, and they have identified a residue in the human
GnRH receptor (Asn7.45) that confers this specificity. Thus, the
R31C change is likely to cause significant loss of GnRH function.
The patient’s pedigree suggests an autosomal dominant mode of
inheritance, with individuals from 3 generations with nIHH. Two
of the patient’s daughters (DNA was not available for her eldest
daughter) and her niece are all heterozygous for the R31C
mutation, consistent with the possibility that the mutation is
responsible for their reproductive phenotypes. However, the
reproductive phenotypes in this family appear somewhat less
severe, because patient 2 exhibited reversal of IHH, and the
patient’s niece had hypothalamic amenorrhea, with her repro-
ductive phenotype becoming apparent only in the presence of an
external stressor.
The R73X variant in patient 3 causes truncation of the GAP
but is predicted to leave the GnRH decapeptide intact. It is
possible that the resulting transcript is rapidly degraded, al-
though the proximity of the premature stop codon to a splice
junction may allow for escape from nonsense-mediated decay
(36). Thus, the effect of this variant on GnRH synthesis is
unclear. Nevertheless, this patient’s pedigree suggests an auto-
somal dominant inheritance pattern with variable expressivity,
because his father had the milder reproductive phenotype of
delayed puberty. The patient’s father is inferred to have carried
the R73X mutation; the fact that the patient’s sister carries the
mutation demonstrates parental transmission, but the patient’s
mother does not carry the mutation.
The T58S change in patient 4 lies in a residue in the GAP
region of the prohormone that is not conserved across species,
and it is unclear whether this conservative amino acid substitu-
tion disrupts GnRH synthesis or function. Also, the consanguin-
ity of his parents implies a recessive mode of inheritance of his
*Database of Single Nucleotide Polymorphisms (dbSNP) (National Center for Biotechnol-
ogy Information, National Library of Medicine, Bethesda, MD), www.ncbi.nlm.nih.gov/
SNP/ [dbSNP accession nos. rs6185–rs6186 (dbSNP Build ID: 129)].
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Fig. 3. Sequence variants in GNRH1 identified in patients with nIHH. (A) Genomic structure of GNRH1. Purple boxes, coding regions of exons; green boxes,
noncoding regions of exons; narrow blue lines, introns; thick blue line, a variant intron within the first exon. (B) Alignment of amino-acid sequences of the GnRH
preprohormone from 4 mammalian species and the peptide sequence predicted to be produced by the G29GfsX12 mutation of patient 1. Yellow, Region
processed to produce the GnRH decapeptide; gray, region that gives rise to the GAP; red, amino acids altered by G29GfsX12 (with premature stop codon indicated
by an asterisk); asterisks below, amino acids altered by sequence variants in GNRH1. (C) Sequence traces indicating base-pair changes (arrows).
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disease. Furthermore, it is unclear how a mutation in GNRH1
could contribute to the patient’s retinitis pigmentosa, although
it is intriguing that GnRH-immunoreactive fibers have been
observed in the mammalian retina (37).
The V18M variant in patient 5, which lies in the signal peptide,
is not predicted to alter signal peptide function. Furthermore, his
nIHH and adrenal insufficiency are readily attributable to his
frameshift mutation in NR0B1/DAX1 (26). Nevertheless, it is
notable that 3 female carriers of the NR0B1/DAX1 mutation in
patient 5’s family had delayed puberty (26) and are also het-
erozygous for the GNRH1 variant. This raises the possibility
that the GNRH1 variant contributed to their reproductive
phenotypes.
How might heterozygous variants in GNRH1 cause or con-
tribute to nIHH? It is possible that our screening strategy failed
to identify mutations in other regions, such as transcriptional
regulatory elements, that disrupt the function of the seemingly
unaffected GNRH1 allele. It is also possible that the heterozy-
gous mutations inGNRH1 do not contribute to the pathogenesis
of nIHH and that only the homozygous frameshift mutation is
causal. However, there is clear precedent for association of
nIHH/KS with heterozygous mutations in FGF8 and PROK2,
which also encode secreted ligands (9, 10, 14, 15). Another
possibility is that heterozygous GNRH1 mutations act in con-
junction with mutations in other genes to cause nIHH, a
mechanism that has been observed for several other nIHH/KS
genes (15, 38–40). It is also possible that some mutations in
GNRH1 have dominant effects. One potential mechanism is
exemplified by mutations in AVP that cause autosomal dominant
neurohypophyseal diabetes insipidus because of neurotoxicity of
the mutant gene products (reviewed in ref. 41); mutations in
GNRH1 may have similar effects. In particular, the R31C
mutation in patient 2 could potentially form inappropriate
disulfide bonds, resulting in misfolded peptides or aggregates
that interfere with the function of the endoplasmic reticulum and
cause GnRH neuronal dysfunction.
GNRH1 is an obvious candidate gene for nIHH, so why have
mutations inGNRH1 not been identified to date?One possibility
is that functional mutations in genes encoding ligands arise less
frequently than in genes encoding receptors because of differ-
ences in size between ligands and their cognate receptors.
Encoding a peptide product of only 92 aa, GNRH1 represents a
smaller ‘‘target’’ for mutation than the 328 aa encoded by
GNRHR. Indeed, for other ligand–receptor pairs implicated in
nIHH/KS, fewer mutations have been reported in genes encod-
ing ligands (FGF8 and PROK2) than in genes encoding receptors
(FGFR1 and PROKR2; refs. 9, 10, and references therein). An
alternative explanation for the rarity ofGNRH1mutations is that
they are rapidly eliminated from the population. This could
occur from inability to transmit mutations to future generations,
as would be expected from mutations that cause a reduction in
fertility. The expression ofGNRH1 in the placenta (29) raises the
possibility that mutations may cause lethality, which would also
lead to elimination of mutations from the population, although
again patient 1’s normal gestation argues against an essential role
for zygotic GnRH in the placenta.
Our study fills a long-standing gap in the genetics of nIHH.
The finding of a homozygous mutation in a patient with nIHH
firmly establishes mutations inGNRH1 as a rare cause of nIHH.
Furthermore, the discovery of heterozygous GNRH1 changes in
patients with familial nIHH suggests that mutations in GNRH1
may also act in a dominant fashion. These patients offer a rare
opportunity to study the effects of human GnRH deficiency
throughout the life cycle and may provide insight into functions
of GnRH outside the hypothalamus.
Methods
Patients. All studies were approved by the Institutional Review Board (IRB) of
MGH, and informed consent was obtained from all patients enrolled in the
study. Participants in the study were either evaluated clinically by the Repro-
ductive Endocrine Associates of MGH or were referred directly by their phy-
sicians to participate in our genetic studies. The diagnosis of nIHH was based
on the absence of spontaneous puberty and low sex steroids (testosterone,
3.4 nmol/L; estradiol, 73 pmol/L) in the setting of inappropriately normal
or low gonadotropin levels and an intact sense of smell. Additional evidence
for a diagnosis of nIHH was provided by the following: (i) absence of LH pulses
during 12–24 h of blood sampling every 10 min (see SI Methods); (ii) normal
basal and stimulated levels of thyroid-stimulating hormone, prolactin, growth
hormone, and cortisol; and (iii) absence of abnormalities on imaging of the
hypothalamic-pituitary region. Whenever possible, patients were interviewed
by both a clinical investigator and a genetics counselor by using an IRB-
approved questionnaire so that a full family pedigree could be obtained.
Control subjects were also evaluated at MGH with detailed histories and
physical examinations.
Of the 310 patients with nIHH screened, 212 were Caucasian, 12 African-
American, 23 Asian, 1 Native American, 3 mixed race, and 59 not assessed for
ethnicity. Of the 192 control subjects, 154 were Caucasian, 34 Asian, 2 Native
Hawaiian/Pacific Islander, and 2 mixed race.
Sequence Analysis. Genomic DNA was extracted from peripheral blood leu-
kocytes or cultured white blood cells. All exons ofGNRH1 and 50 bp of intronic
DNA flanking each exon were sequenced by Polymorphic DNA Technologies.
Sequence variants found in patients but not controls were verified by ampli-
fication of the GNRH1 coding region by PCR by using Taq polymerase (Fisher
Scientific) under standard conditions with the following primers: for exon 1,
5-CTCTGACTTCCATCTTCTGC-3 and 5-GCCTTATCTCACCTGGAGC-3 (anneal-
ing temperature, 60 °C); for exon 2, 5-CTGCAACTTTCCCAATCTCC-3 and
5-GAGGAGTCAGGAATGTAAGC-3 (annealing temperature, 55 °C); and for
exon 3, 5-CTTAGCACTAACTAGAGC-3 and 5-GTGCAACTTGGTGTAAGG-3
(annealing temperature, 49 °C). PCR products were purified by using the
QIAquick PCR Purification kit (Qiagen) and sequenced with the same primers
by the MGH DNA Sequencing Core. FGFR1 and PROKR2 were sequenced as
described in refs. 42 and 43, respectively. Signal peptide recognition and
cleavage were predicted by using SignalP 3.0 (44) and Sig-Pred (45).
Note Added in Proof. Bouligand et al. (46) recently reported a homozygous
frameshift mutation in two siblings with IHH.
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